Angiotech and Boston Scientific welcome journal article noting important differences between drug-eluting stent brands

    VANCOUVER, May 11 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP) today announced its corporate partner, Boston Scientific
Corporation, has welcomed the publication of an article in the current edition
of the Journal of the American College of Cardiology (JACC) reviewing data on
more than 19,000 patients from the Swedish national registry who were
evaluated for restenosis, or the re-narrowing or arteries after percutaneous
coronary intervention (PCI). The article reported that patients who received a
TAXUS(R) Liberté(R) Paclitaxel-Eluting Stent had numerically lower incidences
of repeat procedures to treat restenosis at two years as compared to patients
treated with 'olimus-based drug-eluting stents (DES), including Cordis'
Cypher(R) Stent and Medtronic's Endeavor(R) Stent. In the patients with
diabetes, the TAXUS Liberté Stent demonstrated a statistically significant
lower restenosis rate compared to the Endeavor Stent, which had more than two
times the risk of repeat procedures.
    The Swedish Coronary Angiography and Angioplasty Registry holds data on
all patients undergoing PCI in Sweden. The objective of this independent study
was to evaluate restenosis rates of drug-eluting stents in patients with and
without diabetes in a real-world setting. The JACC article reported that both
the TAXUS Liberté Stent and Boston Scientific's first-generation DES -- the
TAXUS(R) Express(R) Stent -- were the only stents in the study showing no
increased risk of restenosis for patients with diabetes as compared to those
without diabetes. Both the Cypher Stent and Endeavor Stent showed significant
increased risk of restenosis in patients with diabetes. In addition, the study
showed that the TAXUS Liberté Stent had an approximately 23 percent lower
restenosis rate at two years compared to the prior-generation TAXUS Express
Stent. The authors concluded that "There seem to be important differences
between different brands of DES."(1)
    "The results of this study are noteworthy for TAXUS Liberté, which
compared favorably in rates of repeat procedures to both 'olimus stents," said
Donald S. Baim, M.D., Chief Medical and Scientific Officer of Boston
Scientific. "The findings presented in the article are consistent with our own
clinical trial observations, including recently published ARRIVE and ATLAS
data, and may reflect the different mechanism of action for paclitaxel
compared to the 'olimus agents used in the other drug-eluting stents. The
newer and thinner-strut TAXUS Liberté Stent performed better than the TAXUS
Express Stent in reducing restenosis."
    The Swedish registry study included four DES brands: TAXUS Liberté, TAXUS
Express, Cypher and Endeavor. In total, the registry included 35,478 DES
implants during 22,962 procedures in 19,004 patients, with 1,807 restenoses
reported over a mean 29-month follow-up period. For the entire study
population, the repeat revascularization rate per stent was 3.5 percent after
one year and 4.9 percent after two years. Overall, the adjusted risk of
restenosis was 1.23 times higher in patients with diabetes than in patients
without diabetes. In patients with diabetes, restenosis was higher in the
non-TAXUS Stents. The sirolimus-eluting Cypher Stent and the
zotorolimus-eluting Endeavor Stent had higher restenosis rates in patients
with diabetes compared with those in patients without diabetes (1.25 times and
1.77 times, respectively).
    TAXUS Stents have been evaluated by the industry's most extensive
randomized, controlled clinical trial program, with follow-up to five years in
some cases. These trial results have been supplemented by data on more than
35,000 patients enrolled in post-approval registries. To date, approximately
11 million Boston Scientific stents have been implanted globally, making them
the world's most frequently used stents.
    The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System received U.S.
Food and Drug Administration approval in October 2008, and received European
CE Mark approval for use in patients with diabetes in December 2007. In the
U.S., the TAXUS Stents are not specifically indicated for use in patients with

    (1) J Am Coll Cardiol 2009;53:1660-7

    Forward Looking Statements
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for 2009 and beyond, our strategies
or future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research, development, product
and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are taken into
account as part of our assumptions underlying these forward-looking statements
and include, among others, the following: general economic and business
conditions, both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing products or our
ability to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; adverse results or unexpected delays in pre-clinical
and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for
substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2008 filed with the SEC on Form
10-K, and our quarterly report for the three months ended March 31, 2009 filed
with the SEC on Form 10-Q.

    Given these uncertainties, assumptions and risk factors, readers are
    cautioned not to place undue reliance on such forward-looking statements.
    Except as required by law, we disclaim any obligation to update any such
    factors or to publicly announce the result of any revisions to any of the
    forward-looking statements contained in this press release to reflect
    future results, events or developments.

    (C) 2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890